

#2
2/22

OIPÉ

RAW SEQUENCE LISTING

DATE: 02/19/2002

PATENT APPLICATION: US/10/056,583

TIME: 11:07:51

Input Set : A:\HVD 17.APP

Output Set: N:\CRF3\02192002\J056583.raw

ENTERED

4 <110> APPLICANT: Presidents and Fellows of Harvard College
5 Strominger, Jack L.
6 Fridkis-Hareli, Masha
8 <120> TITLE OF INVENTION: THERAPEUTIC PEPTIDES FOR DEMYELINATING
9 CONDITIONS
11 <130> FILE REFERENCE: 24655-017
C--> 13 <140> CURRENT APPLICATION NUMBER: US/10/056,583
14 <141> CURRENT FILING DATE: 2002-01-24
16 <150> PRIOR APPLICATION NUMBER: 60/263,569
17 <151> PRIOR FILING DATE: 2001-01-24
19 <160> NUMBER OF SEQ ID NOS: 99
21 <170> SOFTWARE: FastSEQ for Windows Version 4.0
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 15
25 <212> TYPE: PRT
26 <213> ORGANISM: Homo sapiens
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Immunodominant peptide of MBP, recognized by
30 HLA-DR2 haplotype
32 <221> NAME/KEY: DOMAIN
33 <222> LOCATION: 85 - 99
35 <400> SEQUENCE: 1
36 Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg
37 1 5 10 15
40 <210> SEQ ID NO: 2
41 <211> LENGTH: 15
42 <212> TYPE: PRT
43 <213> ORGANISM: Artificial Sequence
45 <220> FEATURE:
46 <223> OTHER INFORMATION: The peptide was designed and synthesized.
48 <400> SEQUENCE: 2
49 Ala Lys Lys Glu Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
50 1 5 10 15
53 <210> SEQ ID NO: 3
54 <211> LENGTH: 15
55 <212> TYPE: PRT
56 <213> ORGANISM: Artificial Sequence
58 <220> FEATURE:
59 <223> OTHER INFORMATION: The peptide was designed and synthesized.
61 <400> SEQUENCE: 3
62 Ala Lys Glu Glu Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
63 1 5 10 15
66 <210> SEQ ID NO: 4

RAW SEQUENCE LISTING

DATE: 02/19/2002

PATENT APPLICATION: US/10/056,583

TIME: 11:07:51

Input Set : A:\HVD 17.APP

Output Set: N:\CRF3\02192002\J056583.raw

67 <211> LENGTH: 15
68 <212> TYPE: PRT
69 <213> ORGANISM: Artificial Sequence
71 <220> FEATURE:
72 <223> OTHER INFORMATION: The peptide was designed and synthesized.
74 <400> SEQUENCE: 4
75 Ala Lys Glu Ala Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
76 1 5 10 15
79 <210> SEQ ID NO: 5
80 <211> LENGTH: 15
81 <212> TYPE: PRT
82 <213> ORGANISM: Artificial Sequence
84 <220> FEATURE:
85 <223> OTHER INFORMATION: The peptide was designed and synthesized.
87 <400> SEQUENCE: 5
88 Ala Glu Lys Glu Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
89 1 5 10 15
92 <210> SEQ ID NO: 6
93 <211> LENGTH: 15
94 <212> TYPE: PRT
95 <213> ORGANISM: Artificial Sequence
97 <220> FEATURE:
98 <223> OTHER INFORMATION: The peptide was designed and synthesized.
100 <400> SEQUENCE: 6
101 Glu Lys Lys Ala Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
102 1 5 10 15
105 <210> SEQ ID NO: 7
106 <211> LENGTH: 15
107 <212> TYPE: PRT
108 <213> ORGANISM: Artificial Sequence
110 <220> FEATURE:
111 <223> OTHER INFORMATION: The peptide was designed and synthesized.
113 <400> SEQUENCE: 7
114 Lys Glu Glu Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
115 1 5 10 15
118 <210> SEQ ID NO: 8
119 <211> LENGTH: 15
120 <212> TYPE: PRT
121 <213> ORGANISM: Artificial Sequence
123 <220> FEATURE:
124 <223> OTHER INFORMATION: The peptide was designed and synthesized.
126 <400> SEQUENCE: 8
127 Ala Glu Lys Ala Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
128 1 5 10 15
131 <210> SEQ ID NO: 9
132 <211> LENGTH: 15
133 <212> TYPE: PRT
134 <213> ORGANISM: Artificial Sequence
136 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 02/19/2002

PATENT APPLICATION: US/10/056,583

TIME: 11:07:51

Input Set : A:\HVD 17.APP

Output Set: N:\CRF3\02192002\J056583.raw

```

137 <223> OTHER INFORMATION: The peptide was designed and synthesized.
139 <400> SEQUENCE: 9
140 Glu Lys Ala Ala Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
141 1 5 10 15
144 <210> SEQ ID NO: 10
145 <211> LENGTH: 15
146 <212> TYPE: PRT
147 <213> ORGANISM: Artificial Sequence
149 <220> FEATURE:
150 <223> OTHER INFORMATION: The peptide was designed and synthesized.
152 <400> SEQUENCE: 10
153 Glu Glu Lys Ala Tyr Ala Ala Ala Ala Ala Ala Ala Ala Ala
154 1 5 10 15
157 <210> SEQ ID NO: 11
158 <211> LENGTH: 15
159 <212> TYPE: PRT
160 <213> ORGANISM: Artificial Sequence
162 <220> FEATURE:
163 <223> OTHER INFORMATION: The peptide was designed and synthesized.
165 <400> SEQUENCE: 11
166 Ala Lys Glu Ala Ala Ala Ala Tyr Ala Ala Ala Ala Ala Ala
167 1 5 10 15
170 <210> SEQ ID NO: 12
171 <211> LENGTH: 15
172 <212> TYPE: PRT
173 <213> ORGANISM: Artificial Sequence
175 <220> FEATURE:
176 <223> OTHER INFORMATION: The peptide was designed and synthesized.
178 <400> SEQUENCE: 12
179 Glu Lys Glu Ala Ala Ala Ala Tyr Ala Ala Ala Ala Ala Ala
180 1 5 10 15
183 <210> SEQ ID NO: 13
184 <211> LENGTH: 15
185 <212> TYPE: PRT
186 <213> ORGANISM: Artificial Sequence
188 <220> FEATURE:
189 <223> OTHER INFORMATION: The peptide was designed and synthesized.
191 <400> SEQUENCE: 13
192 Lys Glu Lys Ala Ala Ala Ala Tyr Ala Ala Ala Ala Ala Ala
193 1 5 10 15
196 <210> SEQ ID NO: 14
197 <211> LENGTH: 15
198 <212> TYPE: PRT
199 <213> ORGANISM: Artificial Sequence
201 <220> FEATURE:
202 <223> OTHER INFORMATION: The peptide was designed and synthesized.
204 <400> SEQUENCE: 14
205 Ala Lys Ala Glu Ala Ala Ala Tyr Ala Ala Ala Ala Ala Ala
206 1 5 10 15

```

RAW SEQUENCE LISTING

DATE: 02/19/2002

PATENT APPLICATION: US/10/056,583

TIME: 11:07:51

Input Set : A:\HVD 17.APP

Output Set: N:\CRF3\02192002\J056583.raw

```

209 <210> SEQ ID NO: 15
210 <211> LENGTH: 15
211 <212> TYPE: PRT
212 <213> ORGANISM: Artificial Sequence
214 <220> FEATURE:
215 <223> OTHER INFORMATION: The peptide was designed and synthesized.
217 <400> SEQUENCE: 15
218 Ala Glu Lys Ala Ala Ala Tyr Ala Ala Ala Ala Ala Ala
219 1          5          10          15
222 <210> SEQ ID NO: 16
223 <211> LENGTH: 15
224 <212> TYPE: PRT
225 <213> ORGANISM: Artificial Sequence
227 <220> FEATURE:
228 <223> OTHER INFORMATION: The peptide was designed and synthesized.
230 <400> SEQUENCE: 16
231 Ala Lys Lys Ala Ala Glu Ala Tyr Ala Ala Ala Ala Ala Ala
232 1          5          10          15
235 <210> SEQ ID NO: 17
236 <211> LENGTH: 15
237 <212> TYPE: PRT
238 <213> ORGANISM: Artificial Sequence
240 <220> FEATURE:
241 <223> OTHER INFORMATION: The peptide was designed and synthesized.
243 <400> SEQUENCE: 17
244 Ala Lys Ala Ala Ala Ala Glu Tyr Ala Ala Ala Ala Ala Ala
245 1          5          10          15
248 <210> SEQ ID NO: 18
249 <211> LENGTH: 15
250 <212> TYPE: PRT
251 <213> ORGANISM: Artificial Sequence
253 <220> FEATURE:
254 <223> OTHER INFORMATION: The peptide was designed and synthesized.
256 <400> SEQUENCE: 18
257 Ala Glu Lys Ala Tyr Ala Ala Tyr Ala Ala Ala Ala Ala Ala
258 1          5          10          15
261 <210> SEQ ID NO: 19
262 <211> LENGTH: 15
263 <212> TYPE: PRT
264 <213> ORGANISM: Artificial Sequence
266 <220> FEATURE:
267 <223> OTHER INFORMATION: The peptide was designed and synthesized.
269 <400> SEQUENCE: 19
270 Ala Glu Glu Ala Tyr Lys Ala Tyr Ala Ala Ala Ala Ala Ala
271 1          5          10          15
274 <210> SEQ ID NO: 20
275 <211> LENGTH: 15
276 <212> TYPE: PRT
277 <213> ORGANISM: Artificial Sequence

```

RAW SEQUENCE LISTING

DATE: 02/19/2002

PATENT APPLICATION: US/10/056,583

TIME: 11:07:51

Input Set : A:\HVD 17.APP

Output Set: N:\CRF3\02192002\J056583.raw

```

279 <220> FEATURE:
280 <223> OTHER INFORMATION: The peptide was designed and synthesized.
282 <400> SEQUENCE: 20
283 Ala Glu Lys Lys Tyr Ala Ala Tyr Ala Ala Ala Ala Ala Ala
284 1          5          10          15
287 <210> SEQ ID NO: 21
288 <211> LENGTH: 15
289 <212> TYPE: PRT
290 <213> ORGANISM: Artificial Sequence
292 <220> FEATURE:
293 <223> OTHER INFORMATION: The peptide was designed and synthesized.
295 <400> SEQUENCE: 21
296 Ala Ala Glu Lys Tyr Ala Ala Tyr Ala Ala Ala Ala Ala Ala
297 1          5          10          15
300 <210> SEQ ID NO: 22
301 <211> LENGTH: 15
302 <212> TYPE: PRT
303 <213> ORGANISM: Artificial Sequence
305 <220> FEATURE:
306 <223> OTHER INFORMATION: The peptide was designed and synthesized.
308 <400> SEQUENCE: 22
309 Ala Glu Glu Lys Tyr Ala Ala Tyr Ala Ala Ala Ala Ala Ala
310 1          5          10          15
313 <210> SEQ ID NO: 23
314 <211> LENGTH: 15
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <223> OTHER INFORMATION: The peptide was designed and synthesized.
321 <400> SEQUENCE: 23
322 Ala Lys Glu Ala Tyr Ala Ala Tyr Ala Ala Ala Ala Ala Ala
323 1          5          10          15
326 <210> SEQ ID NO: 24
327 <211> LENGTH: 15
328 <212> TYPE: PRT
329 <213> ORGANISM: Artificial Sequence
331 <220> FEATURE:
332 <223> OTHER INFORMATION: The peptide was designed and synthesized.
334 <400> SEQUENCE: 24
335 Ala Ala Lys Glu Tyr Ala Ala Tyr Ala Ala Ala Ala Ala Ala
336 1          5          10          15
339 <210> SEQ ID NO: 25
340 <211> LENGTH: 15
341 <212> TYPE: PRT
342 <213> ORGANISM: Artificial Sequence
344 <220> FEATURE:
345 <223> OTHER INFORMATION: The peptide was designed and synthesized.
347 <400> SEQUENCE: 25
348 Ala Lys Ala Glu Tyr Ala Ala Tyr Ala Ala Ala Ala Ala Ala

```

VERIFICATION SUMMARY

DATE: 02/19/2002

PATENT APPLICATION: US/10/056,583

TIME: 11:07:52

Input Set : A:\HVD 17.APP

Output Set: N:\CRF3\02192002\J056583.raw

L:13 M:270 C: Current Application Number differs, Replaced Current Application Number